Journal
PLACENTA
Volume 60, Issue -, Pages S73-S79Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2017.04.011
Keywords
Congenital cytomegalovirus; Correlates of protection; Maternal immunity; Human CMV; Rhesus model
Funding
- NICHD NIH HHS [DP2 HD075699] Funding Source: Medline
- NIGMS NIH HHS [T32 GM145449, T32 GM007171] Funding Source: Medline
Ask authors/readers for more resources
Human cytomegalovirus (HCMV) is the most common congenitally transmitted pathogen worldwide, impacting an estimated 1 million newborns annually. In a subset of infected infants, congenital HCMV causes severe, long-lasting sequelae, including deafness, microcephaly, neurodevelopmental delay, and even death. Accordingly, a maternal vaccine to prevent congenital HCMV infection continues to be a top public health priority. Nevertheless, all vaccines tested to date have failed to meet clinical trial endpoints. Maternal immunity provides partial protection against congenital HCMV transmission, as vertical transmission from seropositive mothers is relatively rare. Therefore, an understanding of the maternal immune correlates of protection against HCMV congenital infection will be critical to inform design of an efficacious maternal vaccine. This review summarizes our understanding of the innate and adaptive immune correlates of protection against congenital transmission of HCMV, and discusses the advantages and applications of a novel nonhuman primate model of congenital CMV transmission to aid in rational vaccine design and evaluation. (c) 2017 IFPA and Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available